Business Update
(07.12.2023) Oxford Biomedica has made significant progress in its streamlining of operations to become a pure-play quality and innovation-led global cell and gene therapy CDMO. The Company has concluded Read More
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
– Oxford Biomedica announces the signing of a sale and purchase agreement with Institut Mérieux for the acquisition of ABL Europe – The transaction: Provides Oxford Biomedica with multi viral vector CDMO capabilities – to be made available across the Company’s six manufacturing sites in EU, US and UK… Read More
Oxford Biomedica PLC interim results for the six months ended 30 June 2023
Newly appointed Chief Executive Officer, Dr. Frank Mathias, is leading a transformation to position Oxford Biomedica as a pure-play CDMO; strategic and operational streamlining ongoing Transformation into a pure-play CDMO by 1 January 2024, with £30 million of annualised costs savings Strong execution and delivery of commercial strategy evidenced by… Read More
Oxford Biomedica and Institut Mérieux Enter into Exclusive Negotiations with Respect to the Proposed Acquisition by Oxford Biomedica of ABL Europe
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation The Proposed Transaction, would: Provide Oxford Biomedica multi viral vector CDMO capabilities across multiple sites in EU, US and UK… Read More
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it will host a webinar on the TetraVecta™ system, the Company’s 4th generation lentiviral vector delivery system, on Monday 2 October 2023. The webinar titled… Read More
Oxford Biomedica expands agreement with Cabaletta Bio; adding new viral vector programme for CD19-CAR T therapies
Oxford, UK – 22 August 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces that it has expanded its License and Supply Agreement (“LSA”) with Cabaletta Bio, Inc. (Nasdaq: CABA) (“Cabaletta Bio”), a Philadelphia-based clinical-stage biotechnology company focused on developing… Read More
Oxford Biomedica launches the TetraVecta™ System
Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4th generation lentiviral vector delivery system, TetraVectaTM. This state-of-the-art technology developed at Oxford Biomedica elevates the quality, potency and packaging capacity of lentiviral… Read More
2023 AGM Notification
London, UK – 5 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting (“AGM”) together with a copy of the … Read More
2022 Annual Report and Accounts
London, UK – 28 April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “the Company” or “the Group”), a quality and innovation-led viral vector CDMO, gives notice that the 2022 Annual report and accounts is now available on the “Investors” section of the Group’s website… Read More
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20… Read More
Preliminary results for the year ended 31 December 2022
Enhancing our position as a global quality and innovation-led viral vector CDMO Oxford, UK – 25 April 2023: Oxford Biomedica plc (“Oxford Biomedica” or “the Company”) (LSE:OXB), a quality and innovation-led viral vector CDMO, announces its preliminary results for the year ended 31 December 2022. Dr. Frank Mathias, Oxford Biomedica’s Chief… Read More
Oxford Biomedica confirms no exposure to SVB receivership
Oxford, UK – 13 March 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a leading gene and cell therapy group, notes the statement by the US Treasury, Federal Reserve, and FDIC on 12 March 2023 announcing measures to protect all depositors of Silicon Valley Bank (“SVB”) in the United… Read More